Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Cambridge_Antibody_Technology> ?p ?o }
- Cambridge_Antibody_Technology abstract "Cambridge Antibody Technology (officially Cambridge Antibody Technology Group Plc, informally CAT) was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using phage display and ribosome display technology.Technology developed by CAT was used to create adalimumab, the first fully human antibody blockbuster drug. Humira, the brand name of adalimumab, is an anti-TNF antibody discovered by CAT as D2E7, then developed in the clinic and marketed by Abbott Laboratories. The company was also behind belimumab, the anti-BlyS antibody drug marketed as Benlysta and the first new approved drug for systemic lupus in more than 50 years.Founded in 1989, CAT was acquired by AstraZeneca for £702m in 2006. AstraZeneca subsequently acquired MedImmune LLC, which it combined with CAT to form a global biologics division called MedImmune. CAT was often described as the 'jewel in the crown' of the British biotechnology industry and during the latter years of its existence was the subject of frequent acquisition speculation.".
- Cambridge_Antibody_Technology assets "215.98".
- Cambridge_Antibody_Technology equity "180.97".
- Cambridge_Antibody_Technology extinctionYear "2007".
- Cambridge_Antibody_Technology fate "Acquired byAstraZenecain 2006; combined withMedImmunein 2007".
- Cambridge_Antibody_Technology foundationPlace Babraham.
- Cambridge_Antibody_Technology foundedBy David_Chiswell.
- Cambridge_Antibody_Technology foundedBy Greg_Winter.
- Cambridge_Antibody_Technology foundedBy John_McCafferty.
- Cambridge_Antibody_Technology foundedBy Medical_Research_Council_(United_Kingdom).
- Cambridge_Antibody_Technology foundingYear "1989".
- Cambridge_Antibody_Technology internationally "true".
- Cambridge_Antibody_Technology keyPerson Chief_executive_officer.
- Cambridge_Antibody_Technology keyPerson David_Chiswell.
- Cambridge_Antibody_Technology location Cambridgeshire.
- Cambridge_Antibody_Technology location England.
- Cambridge_Antibody_Technology location Granta_Park.
- Cambridge_Antibody_Technology location United_Kingdom.
- Cambridge_Antibody_Technology netIncome "25.25".
- Cambridge_Antibody_Technology numberOfEmployees "300".
- Cambridge_Antibody_Technology operatingIncome "147.25".
- Cambridge_Antibody_Technology owner AstraZeneca.
- Cambridge_Antibody_Technology owningCompany AstraZeneca.
- Cambridge_Antibody_Technology product Adalimumab.
- Cambridge_Antibody_Technology product Belimumab.
- Cambridge_Antibody_Technology revenue "172.5".
- Cambridge_Antibody_Technology service Monoclonal_antibody.
- Cambridge_Antibody_Technology successor MedImmune.
- Cambridge_Antibody_Technology thumbnail Black_with_strap_v2.png?width=300.
- Cambridge_Antibody_Technology type Public_limited_company.
- Cambridge_Antibody_Technology wikiPageExternalLink IP_History.
- Cambridge_Antibody_Technology wikiPageID "23574418".
- Cambridge_Antibody_Technology wikiPageLength "67932".
- Cambridge_Antibody_Technology wikiPageOutDegree "172".
- Cambridge_Antibody_Technology wikiPageRevisionID "706695777".
- Cambridge_Antibody_Technology wikiPageWikiLink Aaron_Klug.
- Cambridge_Antibody_Technology wikiPageWikiLink AbbVie_Inc..
- Cambridge_Antibody_Technology wikiPageWikiLink Abbott_Laboratories.
- Cambridge_Antibody_Technology wikiPageWikiLink Acute_lymphoblastic_leukemia.
- Cambridge_Antibody_Technology wikiPageWikiLink Adalimumab.
- Cambridge_Antibody_Technology wikiPageWikiLink Amgen.
- Cambridge_Antibody_Technology wikiPageWikiLink Anthrax.
- Cambridge_Antibody_Technology wikiPageWikiLink Anti-CD22_immunotoxin.
- Cambridge_Antibody_Technology wikiPageWikiLink AstraZeneca.
- Cambridge_Antibody_Technology wikiPageWikiLink Automation.
- Cambridge_Antibody_Technology wikiPageWikiLink B-cell_chronic_lymphocytic_leukemia.
- Cambridge_Antibody_Technology wikiPageWikiLink Babraham.
- Cambridge_Antibody_Technology wikiPageWikiLink Babraham_Institute.
- Cambridge_Antibody_Technology wikiPageWikiLink Belimumab.
- Cambridge_Antibody_Technology wikiPageWikiLink Bertilimumab.
- Cambridge_Antibody_Technology wikiPageWikiLink Biotechnology.
- Cambridge_Antibody_Technology wikiPageWikiLink Board_of_directors.
- Cambridge_Antibody_Technology wikiPageWikiLink Briakinumab.
- Cambridge_Antibody_Technology wikiPageWikiLink CD22.
- Cambridge_Antibody_Technology wikiPageWikiLink CSL_Limited.
- Cambridge_Antibody_Technology wikiPageWikiLink Cambridge.
- Cambridge_Antibody_Technology wikiPageWikiLink Cambridgeshire.
- Cambridge_Antibody_Technology wikiPageWikiLink Category:1989_establishments_in_England.
- Cambridge_Antibody_Technology wikiPageWikiLink Category:AstraZeneca.
- Cambridge_Antibody_Technology wikiPageWikiLink Category:Companies_based_in_Cambridge.
- Cambridge_Antibody_Technology wikiPageWikiLink Category:Companies_established_in_1989.
- Cambridge_Antibody_Technology wikiPageWikiLink Category:Companies_formerly_listed_on_NASDAQ.
- Cambridge_Antibody_Technology wikiPageWikiLink Category:Monoclonal_antibodies.
- Cambridge_Antibody_Technology wikiPageWikiLink Category:Pharmaceutical_companies_of_England.
- Cambridge_Antibody_Technology wikiPageWikiLink Celera_Corporation.
- Cambridge_Antibody_Technology wikiPageWikiLink Celltech.
- Cambridge_Antibody_Technology wikiPageWikiLink Chief_executive_officer.
- Cambridge_Antibody_Technology wikiPageWikiLink Chief_technology_officer.
- Cambridge_Antibody_Technology wikiPageWikiLink Cooperative_research_and_development_agreement.
- Cambridge_Antibody_Technology wikiPageWikiLink Crohns_disease.
- Cambridge_Antibody_Technology wikiPageWikiLink César_Milstein.
- Cambridge_Antibody_Technology wikiPageWikiLink DRI_Capital.
- Cambridge_Antibody_Technology wikiPageWikiLink Danisco.
- Cambridge_Antibody_Technology wikiPageWikiLink David_Chiswell.
- Cambridge_Antibody_Technology wikiPageWikiLink David_Sainsbury,_Baron_Sainsbury_of_Turville.
- Cambridge_Antibody_Technology wikiPageWikiLink Design_Council.
- Cambridge_Antibody_Technology wikiPageWikiLink Electron_microscope.
- Cambridge_Antibody_Technology wikiPageWikiLink England.
- Cambridge_Antibody_Technology wikiPageWikiLink Eotaxin.
- Cambridge_Antibody_Technology wikiPageWikiLink Extraordinary_general_meeting.
- Cambridge_Antibody_Technology wikiPageWikiLink Fresolimumab.
- Cambridge_Antibody_Technology wikiPageWikiLink G.D._Searle,_LLC.
- Cambridge_Antibody_Technology wikiPageWikiLink Genencor.
- Cambridge_Antibody_Technology wikiPageWikiLink Genomics.
- Cambridge_Antibody_Technology wikiPageWikiLink Genzyme.
- Cambridge_Antibody_Technology wikiPageWikiLink Georges_J._F._Köhler.
- Cambridge_Antibody_Technology wikiPageWikiLink Germany.
- Cambridge_Antibody_Technology wikiPageWikiLink GlaxoSmithKline.
- Cambridge_Antibody_Technology wikiPageWikiLink Glycoprotein.
- Cambridge_Antibody_Technology wikiPageWikiLink Granta_Park.
- Cambridge_Antibody_Technology wikiPageWikiLink Granulocyte_macrophage_colony-stimulating_factor.
- Cambridge_Antibody_Technology wikiPageWikiLink Greg_Winter.
- Cambridge_Antibody_Technology wikiPageWikiLink Hairy_cell_leukemia.
- Cambridge_Antibody_Technology wikiPageWikiLink Human_Genome_Sciences.
- Cambridge_Antibody_Technology wikiPageWikiLink Human_genome.
- Cambridge_Antibody_Technology wikiPageWikiLink Immunotoxin.
- Cambridge_Antibody_Technology wikiPageWikiLink Initial_public_offering.
- Cambridge_Antibody_Technology wikiPageWikiLink Institute_of_Cancer_Research.
- Cambridge_Antibody_Technology wikiPageWikiLink Interleukin_12.
- Cambridge_Antibody_Technology wikiPageWikiLink Interleukin_13.